Exagen (NASDAQ:XGN) Receives Outperform Rating from William Blair

William Blair restated their outperform rating on shares of Exagen (NASDAQ:XGN) in a report issued on Wednesday,RTT News reports.

XGN has been the topic of several other reports. Canaccord Genuity Group boosted their price target on Exagen from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Friday, January 3rd. Cantor Fitzgerald restated an “overweight” rating and set a $8.00 price objective on shares of Exagen in a report on Monday, January 13th.

Exagen Stock Performance

Exagen stock opened at $3.33 on Wednesday. The stock’s 50 day moving average price is $3.77 and its 200 day moving average price is $3.57. The firm has a market capitalization of $58.73 million, a PE ratio of -3.54 and a beta of 1.40. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.05 and a current ratio of 4.05. Exagen has a one year low of $1.30 and a one year high of $6.22.

Institutional Investors Weigh In On Exagen

Hedge funds and other institutional investors have recently bought and sold shares of the business. Verus Capital Partners LLC bought a new stake in shares of Exagen in the 3rd quarter valued at approximately $39,000. Corient Private Wealth LLC bought a new stake in shares of Exagen in the 4th quarter valued at approximately $45,000. Virtu Financial LLC bought a new stake in shares of Exagen in the 4th quarter valued at approximately $46,000. Marshall Wace LLP bought a new stake in shares of Exagen in the 4th quarter valued at approximately $66,000. Finally, Northern Trust Corp increased its holdings in shares of Exagen by 16.7% in the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company’s stock valued at $75,000 after acquiring an additional 2,630 shares during the last quarter. 75.25% of the stock is currently owned by hedge funds and other institutional investors.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).